WealthPLAN Partners LLC Has $2.39 Million Stock Position in Amgen Inc. $AMGN

WealthPLAN Partners LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 27.8% in the first quarter, Holdings Channel.com reports. The fund owned 6,780 shares of the medical research company’s stock after selling 2,614 shares during the period. WealthPLAN Partners LLC’s holdings in Amgen were worth $2,386,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Dogwood Wealth Management LLC lifted its position in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the period. Anfield Capital Management LLC increased its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the period. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the 4th quarter valued at $26,000. Tower View Wealth Management LLC lifted its holdings in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC lifted its holdings in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 0.5%

AMGN stock opened at $368.10 on Wednesday. The business has a fifty day moving average price of $343.26 and a 200 day moving average price of $348.66. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29. The stock has a market capitalization of $198.67 billion, a price-to-earnings ratio of 25.62, a P/E/G ratio of 3.61 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the prior year, the business earned $4.90 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts expect that Amgen Inc. will post 22.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research note on Friday, June 5th. Daiwa Securities Group decreased their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a report on Thursday, June 18th. Finally, Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $356.00.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received an upgrade to Zacks Rank #2 (Buy), which signals improving earnings expectations and could help sentiment near term.
• Positive Sentiment: Biotech stocks may be getting a boost from a more favorable M&A backdrop, with Jim Cramer calling biotech “the hottest group in the market” and suggesting deal activity could accelerate.
• Positive Sentiment: Several analysts raised or reaffirmed price targets on AMGN, including Truist lifting its target to $340 and Cantor Fitzgerald reaffirming a neutral stance with a $350 target, which still reflects solid long-term value expectations.
• Neutral Sentiment: Commentary on Amgen’s dividend safety suggests investors are still weighing near-term headwinds against the company’s cash generation and payout profile.
• Negative Sentiment: Amgen initiated broad U.S. recalls of Sensipar and Corlanor tied to CGMP deviations and contamination concerns, raising quality-control questions across multiple lots and dosage strengths.
• Negative Sentiment: Ongoing scrutiny around Tavneos and pipeline uncertainty continue to weigh on the shares, as regulators challenge the drug’s approval and investors reassess future growth prospects.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.